CoChat

Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Chronic myelogenous leukemia (CML) is a clonal malignancy of hematopoietic stem cells featured with the fusion protein kinase BCR-ABL. To elicit the mechanism underlying BCR-ABL stability, we perform a screen against a panel of deubiquitinating enzymes (DUBs) and find that the ubiquitin-specific protease 7 (USP7) drastically stabilizes the BCR-ABL fusion protein. Further studies show that USP7 interacts with BCR-ABL and blocks its polyubiquitination and degradation. Moreover, USP7 knockdown triggers BCR-ABL degradation and suppresses its downstream signaling transduction. In line with this finding, genetic or chemical inhibition of USP7 leads to BCR-ABL protein degradation, suppresses BCR/ABL signaling, and induces CML cell apoptosis. Furthermore, we find the antimalarial artesunate (ART) significantly inhibits USP7/BCR-ABL interaction, thereby promoting BCR-ABL degradation and inducing CML cell death. This study thus identifies USP7 as a putative Dub of BCR-ABL and provides a rationale in targeting USP7/BCR-ABL for the treatment of CML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-021-03732-6

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 USP7 stabilizes BCR-ABL protein in CML cells. A, B HEK293T cells were transfected with individual deubiquitinases for 48 h, followed by WB assay to measure BCR-ABL at the protein levels. 1. USP7; 2. USP9X; 3. USP14; 4. USP8; 5. UCHL1; 6. USP1; 7. USP15; 8. USP13; 9. UCHL5; 10. USP5; 11. USP36; 12. USP25; 13. BAP1; 14. USP11; 15. USP10; 16. USP30; 17. UCHL3; 18. USP29; 19. USP38; 20. USP39; 21. USPL1; 22. USP49; 23. USP28; 24. CYLD; 25. OTUD4; 26. USP52; 27. USP46; 28. USP53; 29. DUB3; 30. USP44; 31. USP48; 32. USP42; 33. USP50; 34. ATXN3; 35. JOSD2; 36. USP45; 37. OTUD5; 38. USP26; 39. OTUB1; 40. USP3; 41. JOSD1; 42. OTUD6B; 43. USP32P2; 44. OTUB2; 45. JOD1; 46. JOSD3; 47. A2O; 48. PARP11; and 49. CTR. C HEK293T cells were transfected with BCR-ABL and USP7 plasmids as indicated for 48 h, followed cell lysate preparation and WB assays. D HEK293T cells were co-transfected BCR-ABL and USP7 or vector control for increasing periods before being harvested for WB.
Fig. 1 USP7 stabilizes BCR-ABL protein in CML cells. A, B HEK293T cells were transfected with individual deubiquitinases for 48 h, followed by WB assay to measure BCR-ABL at the protein levels. 1. USP7; 2. USP9X; 3. USP14; 4. USP8; 5. UCHL1; 6. USP1; 7. USP15; 8. USP13; 9. UCHL5; 10. USP5; 11. USP36; 12. USP25; 13. BAP1; 14. USP11; 15. USP10; 16. USP30; 17. UCHL3; 18. USP29; 19. USP38; 20. USP39; 21. USPL1; 22. USP49; 23. USP28; 24. CYLD; 25. OTUD4; 26. USP52; 27. USP46; 28. USP53; 29. DUB3; 30. USP44; 31. USP48; 32. USP42; 33. USP50; 34. ATXN3; 35. JOSD2; 36. USP45; 37. OTUD5; 38. USP26; 39. OTUB1; 40. USP3; 41. JOSD1; 42. OTUD6B; 43. USP32P2; 44. OTUB2; 45. JOD1; 46. JOSD3; 47. A2O; 48. PARP11; and 49. CTR. C HEK293T cells were transfected with BCR-ABL and USP7 plasmids as indicated for 48 h, followed cell lysate preparation and WB assays. D HEK293T cells were co-transfected BCR-ABL and USP7 or vector control for increasing periods before being harvested for WB.CC BY · PubMed Central
Fig. 2 USP7 upregulates BCR-ABL in CML cells at the protein level. A K562 and KBM5 cells were infected with lentiviral USP7 for 96 h before being collected for WB and RT-PCR assays. B K562 and KBM5 cells were transfected with siUSP7 for 96 h, followed by WB and RT-PCR assays. C K562 cells were transfected with USP7 or scrambled siRNA for 96 h followed by CHX treatment for indicated periods, cell lysates were subjected to WB analysis. D The statistic analysis of CHX chase assay on BCR-ABL/GAPDH in C. E The BCR-ABL plasmid was co-transfected with USP7 or USP25 plasmids into HEK293T cells, 24 h later, cells were collected for WB against indicated proteins. F siUSP7 was transfected into K562 cells for 96 h, followed by WB against indicated proteins. Scr scramble.
Fig. 2 USP7 upregulates BCR-ABL in CML cells at the protein level. A K562 and KBM5 cells were infected with lentiviral USP7 for 96 h before being collected for WB and RT-PCR assays. B K562 and KBM5 cells were transfected with siUSP7 for 96 h, followed by WB and RT-PCR assays. C K562 cells were transfected with USP7 or scrambled siRNA for 96 h followed by CHX treatment for indicated periods, cell lysates were subjected to WB analysis. D The statistic analysis of CHX chase assay on BCR-ABL/GAPDH in C. E The BCR-ABL plasmid was co-transfected with USP7 or USP25 plasmids into HEK293T cells, 24 h later, cells were collected for WB against indicated proteins. F siUSP7 was transfected into K562 cells for 96 h, followed by WB against indicated proteins. Scr scramble.CC BY · PubMed Central
Fig. 3 USP7 interacts with BCR-ABL via both SH3-SH2 and Y-kinase domains. A HEK293T cells were transfected with BCR-ABL and/or USP7 plasmids for 48 h. Cell lysates were then prepared for IP/WB assays as indicated. B, C Cell lysates from K562 and KBM5 were immunoprecipitated with an anti-USP7 antibody (B) or an anti-BCR-ABL antibody (C) before being applied for WB assays. D The schematic draw of BCR-ABL structure. CC coiled-coil domain, ABD actin-binding domain. E HEK293T cells were co-transfected with a USP7 plasmid and BCR-ABL constructs as indicated for 24 h, the cell lysates were subjected to IP/WB assays as indicated. NS not specific.
Fig. 3 USP7 interacts with BCR-ABL via both SH3-SH2 and Y-kinase domains. A HEK293T cells were transfected with BCR-ABL and/or USP7 plasmids for 48 h. Cell lysates were then prepared for IP/WB assays as indicated. B, C Cell lysates from K562 and KBM5 were immunoprecipitated with an anti-USP7 antibody (B) or an anti-BCR-ABL antibody (C) before being applied for WB assays. D The schematic draw of BCR-ABL structure. CC coiled-coil domain, ABD actin-binding domain. E HEK293T cells were co-transfected with a USP7 plasmid and BCR-ABL constructs as indicated for 24 h, the cell lysates were subjected to IP/WB assays as indicated. NS not specific.CC BY · PubMed Central
Fig. 4 USP7 deubiquitinates BCR-ABL in CML cells. A HEK293T cells were transfected with BCR-ABL and/or USP7 plasmids for 48 h. Cell lysates were then prepared for IP/WB assays as indicated. B K562 and KBM5 were infected with lentiviral USP7 for 96 h, followed by cell lysate preparation and IP/WB assays as indicated. C CML cell lines were infected with sgUSP7 for 96 h, followed by cell lysate preparation and IP/WB assays as indicated. D USP7 was knocked out by the specific siRNA and or USP7 plasmids. Forty-eight hours later, cell lysates were then prepared for IP/WB assays as indicated. E HEK293T cells were transfected with BCR-ABL and WT or C223S USP7 plasmids. Twenty-four hours later, cell lysates were prepared for an IP/WB assay as indicated.
Fig. 4 USP7 deubiquitinates BCR-ABL in CML cells. A HEK293T cells were transfected with BCR-ABL and/or USP7 plasmids for 48 h. Cell lysates were then prepared for IP/WB assays as indicated. B K562 and KBM5 were infected with lentiviral USP7 for 96 h, followed by cell lysate preparation and IP/WB assays as indicated. C CML cell lines were infected with sgUSP7 for 96 h, followed by cell lysate preparation and IP/WB assays as indicated. D USP7 was knocked out by the specific siRNA and or USP7 plasmids. Forty-eight hours later, cell lysates were then prepared for IP/WB assays as indicated. E HEK293T cells were transfected with BCR-ABL and WT or C223S USP7 plasmids. Twenty-four hours later, cell lysates were prepared for an IP/WB assay as indicated.CC BY · PubMed Central
Fig. 5 USP7 activates the BCR-ABL signaling pathway in CML cells. A K562 and KBM5 cells were infected with USP7 lentivirus for 96 h before being collected for WB assays against specific proteins as indicated. B, C K562 and KBM5 cells were treated with P5091 for 24 h, followed by WB assays as indicated. D K562 and KBM5 cells were infected with sgUSP7 lentivirus for 96 h before being collected for WB assays against indicated proteins.
Fig. 5 USP7 activates the BCR-ABL signaling pathway in CML cells. A K562 and KBM5 cells were infected with USP7 lentivirus for 96 h before being collected for WB assays against specific proteins as indicated. B, C K562 and KBM5 cells were treated with P5091 for 24 h, followed by WB assays as indicated. D K562 and KBM5 cells were infected with sgUSP7 lentivirus for 96 h before being collected for WB assays against indicated proteins.CC BY · PubMed Central
Fig. 6 USP7 increases CML cell survival. A K562 and KBM5 cells were infected with lentiviral USP7 for 72 h, followed by MTT assay for the indicated periods. B K562 and KBM5 cells were knocked down USP7 by specific siRNAs for 72 h, followed by MTT assay for the indicated periods. C K562 and KBM5 cells were infected with lentiviral sgUSP7 for 72 h, followed by MTT assay for the indicated periods.
Fig. 6 USP7 increases CML cell survival. A K562 and KBM5 cells were infected with lentiviral USP7 for 72 h, followed by MTT assay for the indicated periods. B K562 and KBM5 cells were knocked down USP7 by specific siRNAs for 72 h, followed by MTT assay for the indicated periods. C K562 and KBM5 cells were infected with lentiviral sgUSP7 for 72 h, followed by MTT assay for the indicated periods.CC BY · PubMed Central
Fig. 7 Artesunate suppresses BCR-ABL signaling transduction and enhances CML cell apoptosis with imatinib. A, B K562 and KBM5 cells were treated with ART for 24 h, followed by WB analysis with the specific antibodies. C K562 and KBM5 cells were treated with ART and/or imatinib (IM) for 24 h, and followed by WB analysis with the specific antibodies. D K562 and KBM5 cells were treated with ART and/or imatinib (IM) for 24 h, and followed by Annexin V-FITC/PI staining and flow cytometric analyses.
Fig. 7 Artesunate suppresses BCR-ABL signaling transduction and enhances CML cell apoptosis with imatinib. A, B K562 and KBM5 cells were treated with ART for 24 h, followed by WB analysis with the specific antibodies. C K562 and KBM5 cells were treated with ART and/or imatinib (IM) for 24 h, and followed by WB analysis with the specific antibodies. D K562 and KBM5 cells were treated with ART and/or imatinib (IM) for 24 h, and followed by Annexin V-FITC/PI staining and flow cytometric analyses.CC BY · PubMed Central
Fig. 8 Artesunate induces BCR-ABL degradation by disrupting its interaction with USP7. A After being treated with ART for 24 h, K562 and KBM5 cells were subjected to WB and RT-PCR assays as indicated. B K562 and KBM5 cells were treated with ART for 12 h, followed by bortezomib (BTZ) or vehicle control treatment for another 12 h before being prepared for WB analysis. C K562 and KBM5 cells were treated with ART for 24 h, and the cell lysates were subjected to IP/WB assays with indicated antibodies to measure BCR-ABL ubiquitination levels. D K562 cells were infected with lentiviral USP7 for 72 h, followed by ART treatment for another 24 h before being prepared for IP/WB assays. E, F K562 and KBM5 cells were treated with ART for 24 h, followed by IP/WB assays with indicated antibodies.
Fig. 8 Artesunate induces BCR-ABL degradation by disrupting its interaction with USP7. A After being treated with ART for 24 h, K562 and KBM5 cells were subjected to WB and RT-PCR assays as indicated. B K562 and KBM5 cells were treated with ART for 12 h, followed by bortezomib (BTZ) or vehicle control treatment for another 12 h before being prepared for WB analysis. C K562 and KBM5 cells were treated with ART for 24 h, and the cell lysates were subjected to IP/WB assays with indicated antibodies to measure BCR-ABL ubiquitination levels. D K562 cells were infected with lentiviral USP7 for 72 h, followed by ART treatment for another 24 h before being prepared for IP/WB assays. E, F K562 and KBM5 cells were treated with ART for 24 h, followed by IP/WB assays with indicated antibodies.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 36

Metadata

Authors
Jiang, S., Wang, X., He, Y., Huang, H., Cao, B., Zhang, Z., Liu, J., Wang, Q., Huang, Z., & Mao, X.
Affiliations
  • Soochow University (CN)
  • Guangzhou University of Chinese Medicine (CN)
  • Guangzhou Medical University (CN)
  • First Affiliated Hospital of Guangzhou Medical University (CN)
Corresponding author
  • Huang, Zhenqian
  • Mao, Xinliang
Venue
Cell Death & Disease
Published
2021-05-07
Volume
12
Issue
5
Pages
456-456
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3159744286
Cited by
35
References
33
Citations by year
2026: 3 · 2025: 4 · 2024: 7 · 2023: 10 · 2022: 5 · 2021: 6
FWCI
2.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81770215)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
USP7, BCR-ABL, chronic myeloid leukemia, protein degradation, deubiquitinase, polyubiquitination, apoptosis, artesunate
MeSH terms
Ubiquitin-Specific Peptidase 7, Humans, Transfection, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Apoptosis, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis. https://app.cochat.ai/papers/10.1038/s41419-021-03732-6
The paper
Jiang, S., Wang, X., He, Y., Huang, H., Cao, B., Zhang, Z., Liu, J., Wang, Q., Huang, Z., & Mao, X. (2021). Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis. Cell Death & Disease. https://doi.org/10.1038/s41419-021-03732-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.